The Outcome of CPAP Titration Under Sleep Endoscopy
Primary Purpose
Obstructive Sleep Apnea, CPAP, DISE
Status
Completed
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
CPAP
Sponsored by
About this trial
This is an interventional diagnostic trial for Obstructive Sleep Apnea
Eligibility Criteria
Inclusion Criteria:
- moderate to severe OSA
- ESS >10
Exclusion Criteria:
- ASA > 3
- allergy to Dexmedetomidine
- second or third degree AVB
- severe heart failure Fc class IV
- asthma acute attack
Sites / Locations
- Division of Thoracic Medicine, Chang Gung Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
CPAP pressure (determied by DISE)
CPAP pressure (determined by physician)
Arm Description
Outcomes
Primary Outcome Measures
complaince of CPAP use
CPAP complaince was defined as the use of CPAP is more than 4 hours per day and 5 days per week
Secondary Outcome Measures
sleepiness score
ESS
Full Information
NCT ID
NCT03523013
First Posted
March 26, 2018
Last Updated
September 29, 2020
Sponsor
Chang Gung Memorial Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03523013
Brief Title
The Outcome of CPAP Titration Under Sleep Endoscopy
Official Title
The Outcome of CPAP Titration Under Sleep Endoscopy: A Randomized Controlled Crossover Trial
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
February 1, 2018 (Actual)
Primary Completion Date
December 31, 2019 (Actual)
Study Completion Date
December 31, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chang Gung Memorial Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The outcome of CPAP titration under sleep endoscopy: A randomized controlled crossover trial
Detailed Description
This is the study entitled "The outcome of CPAP titration under sleep endoscopy: A randomized controlled crossover trial". CPAP is first line golden standard treatment for Obstructive sleep apnea (OSA). However, the overall CPAP compliance is about 50%. One of the reasons responsible for the poor compliance is the inadequate pressure setting initially. Therefore, it is crucial for us to find out the adequate pressure as soon as possible. Sleep endoscopy is the way to evaluate upper airway obstruction of OSA patients. Meanwhile, the investigators used CPAP to titrate the adequate pressure to keep upper airway open under sleep endoscopy guidance. While the investigators find out this adequate pressure, the investigators set this pressure into CPAP program, which OSA patient will use for 1 month. To compare the different effect of CPAP under either auto-CPAP titration pressure or sleep endoscopy guidance pressure, those OSA patients will use auto-titration CPAP for 1 month as well. Another highlight of this study is the sedative agent-dexmedetomidine. Dexmedetomidine is a α2 antogonist, which cause patients sedative but less respiratory drive suppression. The mechanism of dexmedetomidine is more physiological for nature sleep.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea, CPAP, DISE
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CPAP pressure (determied by DISE)
Arm Type
Experimental
Arm Title
CPAP pressure (determined by physician)
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
CPAP
Intervention Description
CPAP treatment with different pressure for OSA patients
Primary Outcome Measure Information:
Title
complaince of CPAP use
Description
CPAP complaince was defined as the use of CPAP is more than 4 hours per day and 5 days per week
Time Frame
the change of complaince between baseline, 1 month and 2 months
Secondary Outcome Measure Information:
Title
sleepiness score
Description
ESS
Time Frame
the change of ESS between baseline, 1 month and 2 months
Other Pre-specified Outcome Measures:
Title
sleep quality
Description
PSQ
Time Frame
the change of PSQ between baseline, 1 month and 2 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
moderate to severe OSA
ESS >10
Exclusion Criteria:
ASA > 3
allergy to Dexmedetomidine
second or third degree AVB
severe heart failure Fc class IV
asthma acute attack
Facility Information:
Facility Name
Division of Thoracic Medicine, Chang Gung Memorial Hospital
City
Taipei
ZIP/Postal Code
105
Country
Taiwan
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
35769360
Citation
Wang TY, Huang YC, Lin TY, Ni YL, Lo YL. Outcome of CPAP Titration for Moderate-to-Severe OSA Under Drug-Induced Sleep Endoscopy: A Randomized Controlled Crossover Trial. Front Neurol. 2022 Jun 13;13:882465. doi: 10.3389/fneur.2022.882465. eCollection 2022.
Results Reference
derived
Learn more about this trial
The Outcome of CPAP Titration Under Sleep Endoscopy
We'll reach out to this number within 24 hrs